Fennec Pharmaceuticals (FENC) Stock Forecast & Price Target

Fennec Pharmaceuticals is well positioned on the strength of PEDMARK’s accelerating commercial traction, with adoption expanding across new and existing accounts, deeper utilization, and 2Q26 net product sales of $17.2M, up 78% year over year and 13.6% sequentially. The company is also showing improving financial quality, as total revenue reached $17.9M, non-GAAP adjusted EBITDA turned positive at $2.8M, and cash and equivalents stood at $41.2M, supported by a largely fixed cost base and growing operating leverage. Beyond current U.S. momentum, upside is reinforced by potential NCCN guideline reclassification, a possible royalty stream from the Norgine partnership, Japanese registration efforts, and an exclusivity extension that could support longer-term demand visibility.

Fennec Pharmaceuticals is highly exposed to a single-asset model, with 100% of revenue tied to PEDMARK and no internal pipeline to offset execution or patent setbacks. Its commercial outlook is fragile because revenue depends on AYA patient compounding, accelerated account activation, and formulary access, while reimbursement is vulnerable to guideline changes and pediatric DRG economics that favor compounded STS at 70-90% discounts. Financially, cash was $42M as of December 2025, and the ongoing commercial buildout could force additional capital raises, increasing dilution risk if growth underperforms.